Disclosure of transparency notification from BlackRock, Inc.
Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 28 April 2026 – 6 PM CET
Disclosure of transparency notification from BlackRock, Inc.
Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 22 April 2026.
Notification from BlackRock, Inc.
262,103 shares held through BlackRock Advisors (UK) Limited, 41,249 shares held through BlackRock Asset Management Canada Limited, 4 shares held through BlackRock Financial Management, Inc., 1,107,105 shares held by BlackRock Fund Advisors, 638,568 shares held by BlackRock Institutional Trust Company, National Association, 193 shares held by BlackRock Investment Management (Australia) Limited, 18,034 shares held by BlackRock Investment Management (UK) Limited and 734 shares held by BlackRock Investment Management, LLC.
The total number of 2,067,990 shares corresponds to the same number of voting rights.
66,459 contracts held by BlackRock Advisors, LLC, 59,833 contracts held by BlackRock Financial Management, Inc., 9,894 contracts held by BlackRock Institutional Trust Company, National Association and 9,830 contracts held by BlackRock Investment Management (UK) Limited.
The total number of 146,016 equivalent financial instruments corresponds to the same number of voting rights.
Further information
Ignacio Artola
Global Head of Investor Relations
investors@fagron.com
About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.
The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam.
Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
Attachment